PureTech Health (LON:PRTC) Insider Purchases £939.44 in Stock

PureTech Health plc (LON:PRTC) insider John LaMattina bought 93,944 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were acquired at an average price of GBX 1 per share, with a total value of £939.44.

John LaMattina also recently made the following trade(s):

• On Wednesday, July 8th, John LaMattina purchased 50,000 shares of PureTech Health stock. The stock was bought at an average cost of GBX 119 per share, for a total transaction of £59,500.

PureTech Health Trading Down 0.4%

Shares of LON:PRTC traded down GBX 0.48 during midday trading on Friday, hitting GBX 119.12. The company had a trading volume of 512,639 shares, compared to its average volume of 1,072,302. The company has a current ratio of 6.59, a quick ratio of 2.51 and a debt-to-equity ratio of 6.33. PureTech Health plc has a 12 month low of GBX 104.71 and a 12 month high of GBX 146.40. The firm has a fifty day simple moving average of GBX 127.71 and a 200 day simple moving average of GBX 126.71. The stock has a market cap of £289.96 million, a price-to-earnings ratio of -2.59 and a beta of 0.79.

Analyst Ratings Changes

Separately, Peel Hunt reiterated a “buy” rating and set a GBX 508 price objective on shares of PureTech Health in a report on Monday, July 13th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of GBX 508.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.